News

Cardiol Therapeutics Announces At-The-Market Equity Offering Program

June 09, 2022

Cardiol Therapeutics Appoints Teri Loxam and Chris Waddick to its Board of Directors

May 19, 2022

Cardiol Therapeutics Announces FDA Investigational New Drug Application (IND) Authorization for Multicenter Phase II Open-label Pilot Study of CardiolRx™ for Recurrent Pericarditis

May 17, 2022

Cardiol Therapeutics Announces Year-End 2021 Update on Operations

March 24, 2022

Cardiol Therapeutics to Participate in Cantor Fitzgerald’s Virtual Rare Orphan Disease Summit

March 22, 2022

Cardiol Therapeutics Appoints Jennifer M. Chao to its Board of Directors

March 15, 2022

Cardiol Therapeutics Receives Clearance from the FDA and Regulatory Agencies in Brazil and Mexico for Important Protocol Amendments Designed to Expedite Patient Enrollment in the LANCER Trial

March 01, 2022

Cardiol Therapeutics Appoints Thought Leaders in Cardiovascular Medicine to its Scientific Advisory Board

January 19, 2022

Cardiol Therapeutics Announces Closing of US$50 Million Public Offering

November 05, 2021

Cardiol Therapeutics Announces Pricing of Public Offering of Units

November 03, 2021

TSX:CRDL NASDAQ:CRDL

Sign up to receive the latest news from Cardiol Therapeutics

© 2023 Cardiol Therapeutics Inc. All rights reserved.      Terms of Use      Privacy Policy